<DOC>
	<DOCNO>NCT02314247</DOCNO>
	<brief_summary>This single-arm , multi-center , open-label Phase II study SINE™ compound Selinexor give orally patient relapsed/refractory PTCL CTCL . Approximately 60 patient relapsed refractory PTCL CTCL meet eligibility criteria none exclusion criterion enrol receive Selinexor either disease progression intolerance occur .</brief_summary>
	<brief_title>Efficacy &amp; Safety Study Selinexor Relapsed/Refractory Peripheral T-cell Lymphoma &amp; Cutaneous T-cell Lymphoma</brief_title>
	<detailed_description>This single-arm , multi-center , open-label Phase II study SINE™ compound selinexor give orally patient relapsed/refractory PTCL CTCL . Approximately 60 patient relapsed refractory PTCL CTCL meet eligibility criteria none exclusion criterion enrol receive Selinexor either disease progression intolerance occur . Enrolled patient give Selinexor oral fix 60 mg dose ( equivalent ~35 mg/m2 ) Days 1 3 Weeks 1-4 4-week cycle . There maximum treatment duration . Patients receive supportive therapy mitigate Selinexor side effect , well best supportive care ( BSC ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<criteria>ECOG performance status ≤2 Relapsed refractory disease least one prior systemic regimen . Measurable disease : accord IWC PTCL accord CTCL Response Skin consensus criterion CTCL patient Objective , document evidence disease progression study entry Known active central nervous system ( CNS ) lymphoma Active graftversushost disease allogeneic stem cell transplantation . At least 4 month must elapse since completion allogeneic stem cell transplantation Unable swallow capsule malabsorption syndrome , disease significantly affect gastrointestinal function .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>PTCL</keyword>
	<keyword>CTCL</keyword>
	<keyword>Peripheral T-cell Lymphoma</keyword>
	<keyword>Cutaneous T-cell Lymphoma</keyword>
	<keyword>Karyopharm</keyword>
	<keyword>KPT-330</keyword>
	<keyword>Selinexor</keyword>
</DOC>